Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials

NEW YORK, NY / ACCESSWIRE / April 13, 2017 / These two companies are finding the FDA trial process to be less predictable than anticipated. Apricus has investors optimistic, while Protalix is putting its sunny side up when talking about its FDA Phase III trial drug.

RDI Initiates
Coverage on:

Apricus Biosciences
Inc.

https://ub.rdinvesting.com/news/?ticker=APRI

Protalix Biotherapeutics
Inc.

https://ub.rdinvesting.com/news/?ticker=PLX

Apricus Biosciences spiked 20.56% to close at $2.17 on Wednesday. The stock traded between $1.80 and $2.45 per share on a lower than average volume of 631,678 shares traded. Investors have optimism toward its upcoming 1st quarter, with earnings results due out May 9th. The company reported a net loss of $7.433 million for the year ending December 31, 2016. Its $5.76 million in revenues was offset by a cost of revenue number of $3.891 million. R&D expenses were cut by more than half, while sales and administrative expenses dropped by more than $2 million, compared to the financials submitted on December 31, 2015.

The company has a single product that is currently being marketed – Vitaros, an erectile dysfunction drug. It has two candidates in FDA Phase II clinical trials: fispemifene which is being tested as a treatment for hypogonadism, and RayVa, created for the treatment of Raynaud’s phenomenon.

Access RDI’s Apricus
Biosciences Research Report at:

https://ub.rdinvesting.com/news/?ticker=APRI

Protalix Biotherapeutics dropped 15.27% to close at $1.11 on Wednesday. The stock traded between $0.98 and $1.27 per share on a heavy volume of 17,955,929. The company announced a positive view of its FDA Phase III clinical trial on its candidate drug, alidornase alfa. The comparative results from the study in January of this year showed that the patients, all being treated for cystic fibrosis, saw their conditions worsen since then. The data shows that lung function improvement went from 4.1 in January to 3.4 in March.

Regardless of how one chooses to view the results of the studies, Protalix Biotherapeutics is facing an even larger challenge. The company’s current drug needs to outperform a very similar drug marketed by Roche, Pulmozyme. Roche currently is racking up sales of $650 million annually (in 2016) from the drug, and alidornase alfa, even if it makes it through FDA Phase III, will have to be significantly better to draw attention.

Access RDI’s Protalix
Biotherapeutics Research Report at:

https://ub.rdinvesting.com/news/?ticker=PLX

Our Actionable Research on Apricus Biosciences Inc. (NASDAQ: APRI) and Protalix Biotherapeutics Inc. (NYSE MKT: PLX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated, directly or indirectly, for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 459654